Top 10 Private Equity Investors in Biotechnology & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | Eli Lilly and Company |
| 3 | Casdin Capital |
| 4 | Janus Henderson Investors |
| 5 | Redmile Group |
| 6 | Bristol-Myers Squibb |
| 7 | A&Z Pharmaceuticals |
| 8 | Wellington Management |
| 9 | T. Rowe Price Group |
| 10 | Cormorant Asset Management |
Crossover funds that moved down from public markets appear alongside the traditional buyout franchises. Clinical data readouts and large pharma acquisition appetite set the pace of investment across biotech, with capital concentrating in firms that can underwrite science. These are buyers and control investors. This list is most relevant if you are selling the company, recapitalizing, or seeking a majority partner.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.